Kneat Logo 300 dpi.jpg
Global Leader in Specialty Therapeutics Selects Kneat to Digitize Validation
09 janv. 2025 17h17 HE | kneat.com, inc.
Leading European global therapeutics company more than 20,000 people selects Kneat to digitize its validation processes.
Kneat Logo 300 dpi.jpg
Global Medical Devices Manufacturer Selects Kneat to Digitize Validation
31 oct. 2024 17h13 HE | kneat.com, inc.
Kneat signs a global and diverse medical devices manufacturer for digital validation.
EVAXION_DEEPBLUE_RGB.png
Strong validation of Evaxion’s AI-Immunology™ platform in multiple clinical trials
09 oct. 2024 08h00 HE | Evaxion Biotech
Data from three separate clinical trials documents the strong ability of the AI-Immunology™ platform to select clinically relevant vaccine targets Strongest outcomes are generated by the top-ranked...
kneatlogo.jpg
Kneat Announces Record Revenue for Second Quarter 2024
06 août 2024 17h17 HE | kneat.com, inc.
Kneat's Q2 2024 Growth Accelerates YoY, with Revenue up 45%, Annual Recurring Revenue up 60%, Gross Profit up 63%
kneatlogo.jpg
Kneat Announces Record Revenue for First Quarter 2024
08 mai 2024 17h33 HE | kneat.com, inc.
Kneat maintains 35% year-over-year revenue growth to surpass $10 million quarterly revenue mark, as annual recurring revenue growth accelerates to 57%.
kneatlogo.jpg
Global Healthcare Leader Selects Kneat
28 févr. 2024 07h17 HE | kneat.com, inc.
Kneat has signed a Master Services Agreement with a global provider of critical care products with over 50,000 employees.
kneatlogo.jpg
Kneat Announces Closing of $20 Million Bought Deal Including Full Exercise of Over-Allotment Option
14 févr. 2024 09h04 HE | kneat.com, inc.
Kneat announced the closing of its bought deal: it issued 6,153,880 common shares at $3.25 per share for gross proceeds of $20,000,110.
kneatlogo.jpg
Kneat to Announce 2023 Fourth-Quarter and Fiscal Year Financial Results February 21, 2024
13 févr. 2024 17h12 HE | kneat.com, inc.
Kneat will announce its Q4 2023 results on February 21, 2024 after market close and host a call for investors the following morning.
Emergen logo.png
Clinical Biomarkers Market Size to Reach USD 63.04 Billion in 2032 | Emergen Research
12 déc. 2023 07h31 HE | Emergen Research
Vancouver, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The global clinical biomarkers market is expected to reach a market size of USD 63.04 billion at a steady CAGR of 10.2% in 2032, according to latest...
Future Market Insights.png
Global Bioprocess Validation Market is anticipated to cross US$ 449.03 Million by 2033 end at an aggressive CAGR of 9.20% | Deep analysis by Future Market Insights, Inc. NEWARK, Del, March 31, 2023 (GLOBE NEWSWIRE) -- As per the current market research conducted by FMI, the global Bioprocess Validation Market is expected to record a CAGR of 9.20% from 2023 to 2033....